Iterative Use of AGREE-II by In-House Systematic Review and Guideline Teams to Improve Transparency in the Guideline Development Process

Article type
Authors
Shiau R1, Griffin J1, Relevo R1, Haskin J2, Baptiste D2, Smith R2, Kondo K3
1Cancer Screening, American Cancer Society, Portland, Oregon, USA
2Cancer Screening, American Cancer Society, Atlanta, Georgia, USA
3Cancer Screening, American Cancer Society, Portland, Oregon, USA; Research Integrity, Oregon Health & Science University, Portland, Oregon, USA
Abstract
"Background:
Guidelines must be produced through unbiased, transparent, and evidence-based processes to be useful and trustworthy to clinicians and patients making healthcare decisions. The Appraisal of Guidelines for Research and Evaluation II (AGREE-II) tool was developed to inform guideline reporting and assess methodological rigor in development. Although often used by third parties for appraisal of published guidelines, AGREE-II can also be used by guideline-producing organizations for internal process planning and ongoing quality improvement. Experienced systematic reviewers are uniquely qualified to identify AGREE-II elements in guidelines/supporting materials and provide objective quality assessments based on a priori criteria.

Objective:
To describe a collaborative process between in-house systematic review (SR) and guideline development (GD) teams using AGREE-II to improve the quality of evidence-based guidelines.

Methods:
As part of program development, our department integrated the skills of our recently formed in-house SR team to assess quality of an internally produced guideline using scoring instructions from AGREE-II. Our SR team met to clarify domain definitions and scoring criteria. Each member reviewed the guideline independently and discussed scores and rationale; after discussion, any change was at each reviewer’s discretion. Minor discords persisted across multiple domains. The SR team presented strengths and improvement recommendations to the GD team.

Results:
The teams collectively identified documentation and process improvements necessary to improve the guideline’s AGREE-II score. The guideline was revised, largely to enhance clarity and more explicitly highlight the link between the evidence and recommendations. We re-assessed the guideline, and scores improved across all domains. To improve future processes and streamline future guidelines, we collaboratively developed a template for guideline documentation, development, and writing following AGREE-II domains. Each team used this iterative process as opportunities to share our areas of expertise, resulting in improved robustness of each team’s processes.

Conclusion:
Beyond a tool to improve guideline reporting, organizations can effectively use AGREE-II to create practices that improve transparency and rigor in the GD process and provide greater communication between GD and SR functions.
"